Skip to main content
ADVANCED SEARCH
Log in

ERS 2024

ERS Congress 2024

 7–11 September | Vienna

The theme of this year’s European Respiratory Society Congress was humans and machines: getting the balance right. Leading experts discussed the latest advances in respiratory medicine, across subjects including asthma, COPD, infections, interstitial lung diseases, sleep and breathing disorders, and thoracic oncology. We bring you the latest news from the conference.

PROMISe of inhaled antibiotics for bronchiectasis and P. aeruginosa

Inhaled colistimethate sodium could help prevent exacerbations in patients with bronchiectasis and Pseudomonas aeruginosa infection.

Read more

Respiratory Medicine Update

Covering the latest advances and keeping your practice up to date. Receive newsletters personally curated for the busy pulmonologist.

Subscribe now

Sulthiame shows potential in OSA

Sulthiame 200 or 300 mg shows promise as a drug therapy for obstructive sleep apnea, reducing sleep disordered breathing and improving sleep quality.

Voice changes alert to COPD exacerbation

Early symptoms of a COPD exacerbation are accompanied by changes in the voice, meaning voice analysis may in the future help to recognize exacerbations early and allow timely interventions. 

Ultra-long-acting biologic reduces severe asthma exacerbations

Two doses of depemokimab over a year can significantly reduce the risk for severe asthma exacerbations compared with placebo.

Digital coach reduces errors in asthma medication inhalation

A digital coach in the form of an app helps asthma patients use their inhalation medication correctly. 

Air pollution worsens respiratory conditions

High ambient air pollution can worsen respiratory conditions and increase the need for hospitalization.

Read more

Depemokimab: a new option for severe asthma

Depemokimab is a new, long-acting biological drug for the treatment of severe eosinophilic asthma. The phase III studies SWIFT-I and SWIFT-II show that it can reduce the annual number of exacerbations. 

Bexotegrast shows potential for disease modification in IPF

Early trial results show that 12 weeks of treatment with the novel agent bexotegrast reduced type 1 collagen deposition in patients with idiopathic pulmonary fibrosis.

Benralizumab new treatment for asthma, COPD exacerbations

Benralizumab as a single injection at the time of an acute exacerbation of asthma or COPD is superior to standard prednisolone.

SPONSORED

Targeting COPD with type 2 inflammation: emerging biologic landscape

1.5 European CME credits (ECMEC®s)

Watch an insightful session tailored for pulmonologists and healthcare professionals eager to enhance their understanding of COPD and the latest advances in biologic therapies.

Sponsored by:
  • Sanofi
Developed by: Springer Healthcare
Watch now
Video

Stay up to date with more from Springer Medicine

Podcast

Episode 12: Defining ARDS

Prof. Giacomo Grasselli takes us through the new concepts and explains why defining ARDS is such a difficult proposition.

Webinar

Keynote webinar | Spotlight on medication adherence

  • Webinar | 27-06-2024 | 18:00 (CEST)

Our experts explain the fundamentals of medication adherence with a practical discussion of how to manage non-adherence in two common scenarios: hypertension and asthma control.

Biomarker-positive disease: personalizing the approach to lung cancer (Link opens in a new window)

A collaborative program highlighting the importance of molecular assessments and targeted treatment selection in people with biomarker-positive disease. Submit your questions for the experts now.

Supported by:
  • Roche and Illumina
Developed by: Springer Healthcare IME
Image Credits